35 studies on Mazdutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Skye Peptides | 5 | 99.41% | View COA → |
| Polaris Peptides | 4 | 99.75% | View COA → |
| PGB | 4 | 99.62% | View COA → |
| Peptide Sciences | 4 | 99.45% | View COA → |
| Planet Peptide | 3 | 99.72% | View COA → |
| Uther Peptide | 3 | 99.7% | View COA → |
| Tydes | 3 | 99.69% | View COA → |
| Elite Research Usa | 3 | 99.29% | View COA → |
Recent certificates: #15034 (99.884%) · #19780 (99.677%) · #2128 (98.74%) · #2147 (99.34%) · #12321 (99.152%) · #19301 (99.866%)
Manufacturers with published third-party certificates of analysis for Mazdutide. Open a vendor to see every batch we've verified.
This study is critically important because it addresses a significant unmet medical need for effective treatments for cognitive dysfunction in individuals with type 2 diabetes, a population at high risk for dementia. …
The GLORY-1 study successfully completed its 48-week double-blind treatment period, evaluating the efficacy and safety profiles of IBI362 at two distinct doses against placebo. While specific numerical results regardi…
This RANDOMIZED, QUADRUPLE, TREATMENT trial is currently RECRUITING participants, with an estimated completion in December 2028, meaning no results are available yet. The study is meticulously designed to investigate …
As an active Phase 3 study with an estimated completion date of June 2026, specific efficacy and safety results comparing IBI362 and Semaglutide are not yet available. The study is designed to assess the non-inferiori…
The successful completion of this Phase 1 trial is a significant step towards developing a potential new treatment for adolescent obesity. Given the rising prevalence of obesity in young populations and the limited th…
The successful completion of this Phase 1/2 study marks a critical developmental milestone for IBI362 as a potential therapeutic agent for overweight and obesity. Establishing the initial safety profile and understand…
This comprehensive review provides crucial evidence for clinicians to make informed decisions when prescribing pharmacological interventions for weight management in non-diabetic adults. The significant weight loss ob…
This research provides a crucial molecular link between exercise and its anti-aging benefits, identifying betaine as a key mediator. The finding that betaine acts as a 'beneficial mimetic' for long-term exercise is pa…
The successful completion of this Phase 1 study is a critical milestone, as it provides the foundational safety and pharmacokinetic data necessary for advancing LY3305677 into further clinical development. Understandi…
If IBI362 demonstrates superior or comparable efficacy with a favorable safety profile against dulaglutide, it could represent a significant advancement in Type 2 Diabetes management. This would provide a new therapeu…
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
The development of HDM1005 represents a potential new therapeutic avenue for patients with T2DM who struggle with current treatment regimens. If HDM1005 demonstrates superior efficacy or a better safety profile compar…
The successful completion of this Phase III trial could establish IBI362 as a novel and effective treatment option for MAFLD, a condition with limited approved pharmacotherapies. Given the high prevalence of MAFLD in …
The successful completion of this early-phase trial is a significant step forward for IBI362, a novel therapeutic candidate for Type 2 Diabetes. This foundational data on its human safety, tolerability, and drug profi…
This detailed trial design and baseline data publication is crucial as it lays the groundwork for understanding the potential of Mazdutide as a significant new therapeutic option. If Mazdutide demonstrates superior or…
The substantial and clinically meaningful weight loss achieved with once-weekly Mazdutide positions it as a highly promising therapeutic agent for obesity and overweight. The dual agonism of GLP-1 and GIP receptors ap…
This review critically highlights the urgent need for more effective, scalable, and culturally appropriate public health interventions in China. Understanding the specific drivers of the epidemic and the gaps in curre…
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …
This case report provides crucial preliminary evidence supporting the potential of Mazdutide as a comprehensive treatment option for adolescents grappling with the complex interplay of obesity, type 2 diabetes, and hy…
This study highlights the potential of Mazdutide as a highly effective treatment option for type 2 diabetes, particularly in the Chinese adult population, addressing both glycemic control and significant weight manage…
This comprehensive review underscores the critical need for integrated treatment strategies for hyperuricemia, moving beyond single-modality approaches. By combining the strengths of Western pharmacology, Traditional …
This comprehensive evaluation provides critical evidence supporting the superior efficacy of certain long-acting GLP-1 RAs in managing Type 2 Diabetes, particularly concerning glycemic control and weight reduction. Th…
This study provides robust evidence supporting Mazdutide as a highly effective and generally safe therapeutic option for overweight and obesity in non-diabetic adults. The substantial and sustained weight loss observe…
This study highlights Mazdutide's multifaceted therapeutic potential for MASLD, demonstrating its ability to simultaneously improve lipid metabolism, reduce inflammation, and alleviate cellular stress. The significant…
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
If successful, this study could establish Mazdutide as a promising new therapeutic option for Alcohol Use Disorder (AUD), potentially offering a novel mechanism of action (via GLP-1/GIP agonism affecting reward pathwa…
PCOS is a complex condition with significant unmet medical needs, particularly for obese patients struggling with hyperandrogenism and metabolic dysfunction. If Mazdutide proves effective in reducing FAI, it could rep…
Understanding how renal impairment affects IBI362's pharmacokinetics is critically important for patient safety and treatment efficacy. If kidney function significantly alters drug exposure, dose adjustments will be n…
Mazdutide's dual GLP-1R and GCGR agonism offers a unique mechanism that appears to drive superior weight loss and broader metabolic improvements compared to single-target therapies. This comprehensive metabolic benefi…
This study provides compelling evidence for the robust efficacy and favorable safety profile of Mazdutide 9 mg as a potent new treatment for obesity, specifically in Chinese adults. These findings are critical for adv…
Free, no account — handy when you're working with Mazdutide.